吉非替尼获得性耐药的非小细胞肺癌患者临床特点

doi:10.3969/j.issn.1007-3969.2015.03.011

中国癌症杂志 ›› 2015, Vol. 25 ›› Issue (3): 222-229.doi: 10.3969/j.issn.1007-3969.2015.03.011

吉非替尼获得性耐药的非小细胞肺癌患者临床特点

周欣，李晓琴，王秀丽，顾国民，刘春玲

新疆医科大学附属肿瘤医院肺内二科，新疆乌鲁木齐 830011

出版日期:2015-03-30 发布日期:2015-05-18
通信作者: 刘春玲　E-mail:liudeyouxiang66@sina.com

The treatment for acquired drug resistance of clinical characteristics of patients with non-small cell lung cancer

ZHOU Xin, LI Xiaoqin, WANG Xiuli, GU Guomin, LIU Chunling

Department of Pulmonary Medicine, Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi Xinjiang 830011, China

Published:2015-03-30 Online:2015-05-18
Contact: LIU Chunling E-mail: liudeyouxiang66@sina.com

摘要/Abstract

摘要： 　 背景与目的：以吉非替尼为代表的表皮生长因子受体酪氨酸激酶抑制剂(epidermal growth factor receptor tyrosine kinase inhibitor，EGFR-TKI)在改善晚期非小细胞肺癌(non-small cell lung cancer，NSCLC)疗效与生活质量中的作用已经得到国际多中心临床研究的充分肯定。但对EGFR-TKI有良好疗效的NSCLC患者不可避免地会发生获得性耐药，这将直接影响到EGFR-TKI的疗效。本研究旨在分析NSCLC患者经过吉非替尼治疗后引起获得性耐药的临床特点。方法：回顾性分析了从吉非替尼中获益的NSCLC患者。所有的资料来自2007年1月—2014年1月新疆肿瘤医院的住院患者。对吉非替尼治疗失败患者的获得性耐药的临床表现、疾病进展时间(time to progress，TTP)及进展后生存时间(post-progression survival，PPS)进行回顾性分析。结果：共收集417例NSCLC患者。中位TTP为10.2个月(95%CI：9.5~10.9)。其中女性、不吸烟、肺腺癌患者的TTP显著延长。发生获得性耐药时，63.3%的患者出现恶化症状。疾病进展情况如下：209例(58.4%)原发肺部病变出现进展，137例(38.3%)既往有转移的病变出现进展，194例(54.2%)出现新发转移。表皮生长因子受体(epidermal growth factor receptor，EGFR)野生型比突变型患者有更多的症状恶化、新发的中枢神经系统(central nervous system，CNS)转移的倾向。外显子19缺失和L858R突变的患者在新发转移上有很大不同(41.4% vs 6.3%，P=0.02)。PPS为8.9个月(95%CI：7.4~10.4)。吸烟史、体能状况(performance status，PS)评分、新CNS病变和随后的化疗是PPS的独立因素。结论：获得性耐药的临床表现根据EGFR突变状态和EGFR突变基因型可能会有所不同。此外，在吉非替尼治疗后获得性耐药的NSCLC患者，再进行后续的化疗也带来与PPS有关的临床受益。

关键词: 获得性耐药, 吉非替尼, 表皮生长因子受体酪氨酸激酶抑制剂, 非小细胞肺癌

Abstract: Background and purpose: Non-small cell lung cancer (NSCLC) patients who have good curative effect on epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) will inevitably acquired drug resistance. It will effect the survival directly. In contrast, few studies have found that EGFR-TKI effectively acquired drug resistance in patients with clinical characteristics. We investigated clinical characteristics of NSCLC patients who experienced acquired drug resistance during gefitinib therapy. Methods: To review the treatment from the benefit of patients with non-small cell lung cancer. All of the data were obtained from Jan. 2007 to Jan. 2014 in Xinjiang tumor hospital. The treatment for failure of acquired drug resistance of clinical manifestations, time to progress (TTP) and post-progression survival (PPS) were retrospectively analyzed. Results: The total collection of 417 patients. Median TTP was 10.2 months (95%CI: 9.5-10.9). The TTP of women adenocarcinoma patients who didn’t smoke significantly extended. When acquired drug resistance happened, 63.3% of patients appeared worse symptoms. The progress of the disease is as follows: 209 cases (58.4%) from the primary lesion, 137 cases (38.3%) before the transfer, 194 cases (54.2%) of new happened. Patients of epidermal growth factor receptor (EGFR) wild type had more tendencies of symptomatic deterioration and new central nervous system (CNS) transfer than patients of EGFR mutation type. Patients of exon 19 deletion and L858R mutations on the new transfer were different (41.4% vs 6.3%, P=0.02). PPS was 8.9 months (95%CI:7.4-10.4). Smoking history, performance status (PS) score, new CNS lesions and the subsequent chemotherapy isindependent factors of PPS. Conclusion: This study suggests that the clinical manifestations of acquired drug resistance according to EGFR mutation status and EGFR mutation genotype may be different. In addition, after the treatment of acquired drug resistance in patients with non-small cell lung cancer, the subsequent clinical benefit from chemotherapy are also associated with PPS.

Key words: Gefitinib, Acquired resistance, Epidermal growth factor receptor tyrosine kinase inhibitor, Nonsmall cell lung cancer

周欣,李晓琴,王秀丽,等. 吉非替尼获得性耐药的非小细胞肺癌患者临床特点[J]. 中国癌症杂志, 2015, 25(3): 222-229.

ZHOU Xin, LI Xiaoqin, WANG Xiuli, et al. The treatment for acquired drug resistance of clinical characteristics of patients with non-small cell lung cancer[J]. China Oncology, 2015, 25(3): 222-229.

[1]	朱逸晖, 李　婷, 胡夕春. Trastuzumab deruxtecan的临床研究进展及展望——HER2耐药患者的新希望[J]. 中国癌症杂志, 2021, 31(8): 754-761.
[2]	李海洲, 张艳炜, 许英杰, 杨　门, 张　磊, 韩京军 . miR-933调控KLF6基因影响非小细胞肺癌的作用研究[J]. 中国癌症杂志, 2021, 31(7): 581-588.
[3]	杨　佳, 刘舒媛, 王莹莹, 李盈甫, 马千里, 李　玙, 王永蓉, 李传印, 谭　芳 . 云南省汉族人群TNF-α基因多态性与非小细胞肺癌发生、发展的相关性[J]. 中国癌症杂志, 2021, 31(7): 616-628.
[4]	义维丽, 赵文成, 黄东宁, 覃　莉, 吴新天, 周　斐, 吴凤英 . PD-1单抗治疗非小细胞肺癌相关不良反应及其与疗效的相关性分析[J]. 中国癌症杂志, 2021, 31(3): 203-211.
[5]	赵媛媛, 周建英, 范　云, 王佳蕾, 黄鼎智, 李峻岭, 史美祺, 刘基巍, 姚　煜, 邬　麟, 姚文秀, 张　力 . BRAF V600突变型非小细胞肺癌的治疗进展[J]. 中国癌症杂志, 2021, 31(12): 1145-1152.
[6]	申宇嘉, 傅小龙 . 非小细胞肺癌发生、发展过程中免疫微环境变化及其临床意义[J]. 中国癌症杂志, 2021, 31(11): 1115-1125.
[7]	何　夕, 焦晓栋, 臧远胜. 肿瘤突变负荷在EGFR突变型晚期非小细胞肺癌中的临床研究进展[J]. 中国癌症杂志, 2021, 31(1): 69-75.
[8]	鲁晓腾, 许　青. 基于CT影像特征的非小细胞肺癌复发相关性因素研究[J]. 中国癌症杂志, 2020, 30(8): 636-640.
[9]	张龙富, 姚家美, 蒋冬先, 侯英勇, 张　新 . BIM联合Scribble预测晚期非小细胞肺癌化疗效果[J]. 中国癌症杂志, 2020, 30(11): 865-871.
[10]	方瑜佳, 周　娟, 苏春霞. 非小细胞肺癌肝转移免疫微环境及未来干预策略[J]. 中国癌症杂志, 2020, 30(10): 750-758.
[11]	李　媛. 病理学指导下的非小细胞肺癌个体化免疫治疗[J]. 中国癌症杂志, 2020, 30(10): 770-776.
[12]	杨　光, 张　昆, 王　俊 . Prospero相关同源异形盒蛋白1在非小细胞肺癌中的表达及意义[J]. 中国癌症杂志, 2020, 30(10): 791-797.
[13]	董　磊, 张仲妍 . 靶向IRF2的miR-1290对非小细胞肺癌细胞增殖、侵袭的调控作用及其机制研究[J]. 中国癌症杂志, 2020, 30(1): 32-40.
[14]	叶柯，郑晓丽，葛红，李雪，王浩. TBRG4在肺腺癌中的作用及其机制研究[J]. 中国癌症杂志, 2019, 29(4): 265-271.
[15]	赵雨笛，谭芳，严志凌，李盈甫，戴书颖，周紫云，张新文，刘舒媛，史荔，姚宇峰. CD44基因多态性与宫颈癌及非小细胞肺癌的相关性[J]. 中国癌症杂志, 2019, 29(4): 277-283.

吉非替尼获得性耐药的非小细胞肺癌患者临床特点

The treatment for acquired drug resistance of clinical characteristics of patients with non-small cell lung cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价